We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Open-Label Extension of Other SZ1839 (Iressa) Trials

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00635973
Recruitment Status : Completed
First Posted : March 14, 2008
Last Update Posted : April 22, 2009
Information provided by:

March 7, 2008
March 14, 2008
April 22, 2009
February 2000
Not Provided
Adverse Events [ Time Frame: Every 28 days ]
Same as current
Complete list of historical versions of study NCT00635973 on ClinicalTrials.gov Archive Site
  • Progression Free Survival [ Time Frame: Every 28 days ]
  • Survival [ Time Frame: Every 28 days ]
Same as current
Not Provided
Not Provided
Open-Label Extension of Other SZ1839 (Iressa) Trials
Multi-Centre, Open-Label Extension Trial of Treatment With ZD1839 (Iressa) in Patients Who Have Been Treated in Other ZD1839 Clinical Trials and May Benefit From Continued Monotherapy ZD 1839.
A trial to assess patients who have been treated with Iressa in a previous clinical trial and may benefit from continued treatment with Iressa.
Not Provided
Phase 3
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Drug: Gefitinib (Iressa)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
October 2003
Not Provided

Inclusion Criteria:

  • Received treatment in a previous Iressa clinical trial
  • Provided Informed Consent to participate in the trial
  • 30 days or less since completing the previous Iressa trial.

Exclusion Criteria:

  • Radiotherapy completed more than 14 days before starting treatment in this trial
  • Incomplete healing from prior surgery
  • Withdrawal from previous Iressa trial due to unacceptable toxicity to major organs
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Alison Armour Medical Science Director, AstraZeneca
Not Provided
Not Provided
April 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP